Načítá se...
Is there a room for immune checkpoint inhibitors in early stage non-small cell lung cancer?
Early non-small cell lung cancer (NSCLC) represents 16% of all new NSCLC at diagnosis with a 5-year survival rate of about 60%. Surgical intervention and adjuvant platinum-based chemotherapy represent the cornerstone treatments, but no significant advances have been achieved since several decades in...
Uloženo v:
| Vydáno v: | J Thorac Dis |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
AME Publishing Company
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5994500/ https://ncbi.nlm.nih.gov/pubmed/29951294 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jtd.2018.01.81 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|